A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia

NCT01276353 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Type Dementia

Interventions

DRUG: E2020
DRUG: E2020

Sponsor

Eisai Inc.